quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:17·57d
INSIDERFiling
Ironwood Pharmaceuticals Inc. logo

SVP, CMO, Head-Res&Drug Shetzline Michael sold $59,322 worth of shares (15,570 units at $3.81), decreasing direct ownership by 6% to 521,425 units (SEC Form 4)

IRWD· Ironwood Pharmaceuticals Inc.
Health Care
Original source

Companies

  • IRWD
    Ironwood Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jan 5UpdateCitizens JMP$8.00
  • Apr 15UpdateWells Fargo-
  • Apr 15UpdateJefferies-
  • Apr 14UpdateCitizens JMP-
  • Sep 9UpdateLeerink Partners$5.00
  • Aug 8UpdateCapitalOne$4.00

Related

  • PR17h
    Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.
  • INSIDER37d
    Director Denner Alexander J was granted 4,451 shares and sold $20,530,448 worth of shares (6,730,800 units at $3.05), increasing direct ownership by 2% to 256,309 units (SEC Form 4)
  • INSIDER42d
    Chief Legal Officer John Minardo was granted 136,612 shares, increasing direct ownership by 38% to 500,498 units (SEC Form 4)
  • INSIDER42d
    Chief Financial Officer Martini Gregory S. was granted 136,612 shares, increasing direct ownership by 85% to 297,213 units (SEC Form 4)
  • INSIDER42d
    SVP, CMO, Head-Res&Drug Shetzline Michael was granted 136,612 shares, increasing direct ownership by 26% to 658,037 units (SEC Form 4)
  • INSIDER42d
    Principal Accounting Officer Silver Ronald was granted 163,934 shares, increasing direct ownership by 65% to 416,570 units (SEC Form 4)
  • INSIDER42d
    Chief Commercial Officer Gaskins Tammi L was granted 136,612 shares, increasing direct ownership by 64% to 350,350 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022